1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Zhejiang NHU Co. Ltd. Class A

Zhejiang NHU Co. Ltd. Class A

SSZSE:002001
25.75
CNY
+0.75
(+3.00%)
2.35EPS
12.15P/E
87.35BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.59
1.56
1.44
1.75
2.34
2.8
2.48
3.33
4.83
5.15
4.86
7.03
7.27
7.95
Basic EPS, GAAP
0.33
0.3
0.15
0.45
0.64
0.99
0.7
1.15
1.41
1.17
0.87
1.91
2.21
2.34
Free Cash Flow per Basic Share
0.22
0.13
-0.07
-0.02
0.12
-0.4
-0.8
0.25
0.77
-0.18
0.22
1.78
2.25
- -
Dividend per Share
0.15
0.15
0.16
0.1
0.27
0.31
0.56
0.44
0.59
0.69
0.59
0.54
0.98
1.57
Book Value per Share
2.46
2.63
2.64
3.02
4.51
5.23
5.5
6.25
7.06
7.63
8.03
9.54
10.67
11.35
Tangible Book Value per Share
2.33
2.48
2.47
2.84
4.31
4.82
5.07
5.79
6.56
7.06
7.24
8.73
9.83
10.17
Basic Weighted Avg Shares
2,666
2,673
2,660
2,676
2,668
3,100
3,087
3,099
3,089
3,094
3,108
3,073
3,061
3,068
Sales/Revenue/Turnover
4,238
4,164
3,823
4,696
6,235
8,683
7,660
10,314
14,917
15,934
15,117
21,610
22,251
24,400
Operating Margin (%)
25.76
25.82
10.81
30.48
36.54
40.36
33.36
41.81
35.7
27.93
22.65
33.42
35.85
35.44
Depreciation Expense
301
346
377
346
370
458
562
864
1,223
1,390
1,704
2,223
2,294
- -
Net Income, GAAP
882
808
402
1,203
1,704
3,079
2,165
3,564
4,356
3,620
2,704
5,869
6,764
7,178
Effective Tax Rate (%)
16.71
20.51
18.98
18.31
19.09
14.87
15.29
12.96
13.64
14.15
16.23
15.07
13.34
14.05
Profit Margin (%)
20.82
19.4
10.52
25.61
27.34
35.46
28.27
34.55
29.2
22.72
17.89
27.16
30.4
29.42
Working Capital
3,494
3,325
2,656
3,073
8,712
6,111
5,905
7,144
8,437
6,143
6,263
10,013
12,038
12,655
LT Debt
293
1
97
501
924
388
3,898
4,140
5,152
5,276
6,827
5,331
4,190
3,172
Total Equity
6,571
7,015
7,053
8,090
13,996
16,215
17,063
19,404
21,896
23,662
24,920
29,446
32,961
35,034
Return on Invested Capital (%)
11.91
10.17
4.51
12.72
12.79
17.19
9.8
13.86
15.21
11.53
8.01
16.13
16.97
17.55
Return on Capital (%)
12.74
10.83
5.33
13.07
13.24
17.68
10.54
14.47
16.06
12.17
8.69
16.67
17.43
17.92
Return on Common Equity (%)
13.98
11.9
5.72
15.92
15.48
20.44
13.05
19.61
21.16
15.95
11.18
21.68
21.77
21.92

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,841
4,029
3,707
LT Borrowings
4,187
3,487
3,170
LT Finance Leases
3
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,073
3,073
3,073
Market Capitalization
77,419
106,187
87,347

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
19,435
21,547
20,145
Cash, Cash Equivalents & STI
10,135
11,978
10,042
Accounts Receivable, Net
3,331
3,639
3,770
Inventories
4,649
4,450
4,769
Total Current Liabilities
7,398
7,645
7,490
Payables & Accruals
- -
- -
- -
ST Debt
3,841
4,029
3,707
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.88%
11.26%
11.94%
Free Cash Flow
-83.16%
120.64%
26.01%
Net Income, GAAP
46.87%
22.46%
15.26%
Sales/Revenue/Turnover
21%
18.45%
2.97%
Total Cash Common Dividend
32.88%
21.17%
79.59%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,499
5,346
5,937
5,828
21,610
2025
5,440
5,661
- -
5,609
22,251
2026
6,295
6,835
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
0.43
0.58
0.61
1.91
2025
0.61
0.56
- -
0.47
2.21
2026
0.59
0.71
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.47
0.02
0.03
0.54
2025
0.22
0.52
- -
0.22
0.98
2026
0.01
0.82
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hu Baifan
Full Time Employees
11,508
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 418, Xinchang Dadao West Road Xinchang ZH China 312500
IPO Date
Jun 25, 2004
Website
cnhu.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Zhejiang NHU Co., Ltd. manufactures and markets functional chemicals focused on nutrition, pharmaceuticals, flavors and fragrances, and advanced materials. Founded in 1999 and headquartered at No. 418 Xinchang Dadao West Road, Qixing Sub-district, Xinchang County, Shaoxing, Zhejiang Province, China, the company listed on the Shenzhen Stock Exchange in 2004 as one of the first SME boards under ticker 002001.SZ. It operates production bases in Xinchang, Shangyu, Shandong, and Heilongjiang, with global reach serving over 100 countries and regions through subsidiaries and integrated supply chains. Core products span nutritional additives including vitamins E, A, B12, C, calcium pantothenate, beta-carotene, lutein, astaxanthin, taurine, and coenzyme Q10; flavors and fragrances such as raspberry ketone, linalool, menthol, methionine, and other monomers; pharmaceutical intermediates and active pharmaceutical ingredients; and new materials like polyphenylene sulfide (PPS), polyphthalamide (PPA), long-fiber reinforced thermoplastics (LFT), isophorone diisocyanate (IPDI), HDI, and IPDA, targeting animal and human nutrition, personal care, automotive, electronics, and industrial applications. The company maintains a robust R&D framework with significant investments, including plans for RMB 500 million in 2024 and at least 10 new product launches annually, alongside achievements like ISO 56005 Level 4 certification for innovation management. Recent developments encompass a strategic partnership with Bota Bio announced in June 2024 for biomanufacturing commercialization, integrating synthetic biology for products like Q10 and VB12; domestic drug registration approval for coenzyme Q10 API; launches of new amino acids, menthol products, IPDA, and aliphatic diisocyanates (ADI); ongoing share repurchases totaling over 14.8 million shares by October 2025 under a plan initiated in April 2025; and enhanced ESG ratings to MSCI "A" level plus EcoVadis Gold Medal recognition in 2025. Zhejiang NHU advances "chemical+" and "biological+" strategies, bolstering bio-fermentation capabilities and green processes across its segments.